TRENTON, N.J. — Drugmaker Pfizer said Monday that it will launch a less-expensive version of rival Johnson & Johnson’s blockbuster immune disorder drug, Remicade. Pfizer Inc.’s version, called Inflectra, will hit pharmacies in late November. It will be only the second so-called biosimilar drug available in the U.S. Remicade, long J&J’s top-selling drug, is approved
